ADAR1 Capital Management LLC 13D and 13G filings for Keros Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-05-12 11:29 am Unchanged |
2025-05-12 | 13D | Keros Therapeutics, Inc. KROS |
ADAR1 Capital Management LLC | 5,390,964 13.270% |
0 (Unchanged) |
Filing |
| 2025-05-08 4:39 pm Unchanged |
2025-05-08 | 13D | Keros Therapeutics, Inc. KROS |
ADAR1 Capital Management LLC | 5,390,964 13.270% |
0 (Unchanged) |
Filing |
| 2025-04-28 6:43 pm Unchanged |
2025-04-24 | 13D | Keros Therapeutics, Inc. KROS |
ADAR1 Capital Management LLC | 5,390,964 13.290% |
0 (Unchanged) |
Filing |
| 2025-04-11 8:32 pm Purchase |
2025-04-04 | 13D | Keros Therapeutics, Inc. KROS |
ADAR1 Capital Management LLC | 5,390,964 13.290% |
5,390,964 (New Position) |
Filing |